Biotechnology

Connect Biopharma

Connect Biopharma released FY2026 Q1 earnings on May 12 (EST), actual revenue USD 169K (forecast USD 0), actual EPS USD -0.343 (forecast USD -0.278)

Connect Biopharma released FY2025 Q4 earnings on March 31 (EST), actual revenue USD 0 (forecast USD 2.965 K), actual EPS USD -0.2726 (forecast USD -0.302)

Connect Biopharma released FY2025 annual earnings on March 31 (EST), actual revenue USD 64 K (forecast USD 74.85 K), actual EPS USD -1 (forecast USD -1.026)

Concord Bio-Pharm Announces New Data on Rademikibart and Launches Clinical Trials

Concord BioPharma to Speak at Evercore's 8th Healthcare Conference

Connetec Biopharma Reports Significant Net Loss in Q3 2025 and Continues Clinical Trials and Collaborations

HC Wainwright Downgrades Cendu Biopharmaceutical's EPS Outlook for FY2025

H.C. Wainwright Reiterates Buy Rating on Canbiologics

Connect Biopharma released FY2025 9 Months earnings on November 12 (EST), actual revenue USD 64K, actual EPS USD -0.7267

Connect Biopharma released FY2025 Q3 earnings on November 12 (EST), actual revenue USD 16 K (forecast USD 0), actual EPS USD -0.3087 (forecast USD -0.2375)

Analyst Sees Bright Prospects for Connect Biopharma and Rademikibart

Convenient Biopharm Holdings Announces Phase II Data for Anti-IL-4Rα Antibody

Convenient Biopharma to Announce 2025 Q2 Earnings

Connect Biopharma released FY2025 Q2 earnings on August 13 (EST), actual revenue USD 48K (forecast USD 0), actual EPS USD -0.2324 (forecast USD -0.22)

Connect Biopharma released FY2025 Semi-Annual Earnings on August 13 (EST), actual revenue USD 48 K (forecast USD 0), actual EPS USD -0.42 (forecast USD -0.4)

Concordius Displays Rademikibart Asthma Drug Clinical Data

Convenient Biopharma Showcases Rademikibart Clinical Data

Concordius Biopharm Publishes Q1 Earnings and Launches Rademikibart Phase 2 Study

Connect Biopharma released FY2025 Q1 earnings on May 15 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1855 (forecast USD -0.26)

Converge Biopharma Initiates Seabreeze STAT Study to Assess Rademikibart for COPD

OPTIMI HEALTH CORP

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

HCW Biologics

Micware

Silexion Therapeutics

GCL Global

MetaVia

Vida Global

MicroAlgo

BiomX

CNTB

SBIO

IBBQ

LABU

H.C. Wainwright analyst Brandon Folkes has reiterated a Buy rating on Connect Biopharma Holdings (CNTB) with a price target of $7.00. Folkes, a 3-star analyst, has an average return of 2.0% and a 42.07% success rate. The consensus on CNTB is a Strong Buy, with an average price target of $8.38.

Tip Ranks

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

Heron Therap

Collegium Pharma

Achieve Life Sciences

Connect Biopharma Holdings (CNTB) Gets a Buy from H.C. Wainwright

Earnings Watch

Connect Biopharma | 8-K: FY2026 Q1 Revenue: USD 169 K

Northland Securities analyst Carl Byrnes has maintained a Buy rating on Connect Biopharma Holdings (CNTB) with a price target of $7.50. The overall analyst consensus for CNTB is a Strong Buy, with an average price target of $8.38. Byrnes focuses on the Healthcare sector and has an average return of -4.7% with a 35.65% success rate on his stock recommendations.

BioLife Solutions

Spectral AI

Avita Medical

SPECTRAL AI INC C/WTS 11/09/2028(TO PUR COM)

Northland Securities Remains a Buy on Connect Biopharma Holdings (CNTB)

Connect Biopharma | 10-K: FY2025 Revenue: USD 64 K

LABD

Connect Biopharma Holdings Ltd. (CNTB) has announced the advancement of enrolment in the Phase 2 Seabreeze STAT trial for its asthma drug Rademikibart, following a favorable review by an independent data monitoring committee. Rademikibart, a monoclonal antibody targeting IL-4Ra, aims to treat Th2 inflammatory diseases. The committee's interim analysis showed no safety concerns after treating at least 50 patients. Topline data is expected by mid-2026, and the company will coordinate with the FDA for the Phase 3 trial.

nasdaq

Direxion S&P Biotech Bear 3X

Nasdaq

Connect Biopharma Advances Enrolment In Phase 2 Seabreeze STAT Trial For Asthma Drug Rademikibart

Connect Biopharma Holdings (CNTB) announced that an independent Data Monitoring Committee completed a positive interim efficacy analysis of its Phase 2 Seabreeze STAT trials for rademikibart, with no safety concerns and no need to change sample size. The company plans to engage the FDA for a Phase 3 program and aims to deliver topline data in mid-2026. Analysts rate CNTB stock as a Buy with a $7.00 price target, though concerns about financial performance persist. Connect Biopharma focuses on treatments for asthma and COPD, positioning rademikibart as a leading therapy in the market.

SIMCERE PHARMA

Connect Biopharma Advances Rademikibart After Positive Interim Review

CANG

ZLAB

BTBT

HSAI

RERE

Cango(CANG) rose 29.73%, with a trading turnover 8.6 Million USD, and a year-to-date fell 68%. ECARX(ECX) rose 8.4%, with a trading turnover 3.0 Million USD, and a year-to-date fell 25%. MMTEC(MTC) fell 6.73%, with a trading turnover 1.1 Million USD, and a year-to-date rose 78.4%. Hesai(HSAI) fell 5.81%, with a trading turnover 41.8 Million USD, and a year-to-date fell 2.2%.

- The Nasdaq Composite Index fell 0.26% but is up 5% year-to-date.  
- The S&P 500 Index decreased by 0.24% with a year-to-date gain of 3.9%, while the Dow Jones Index dropped 0.01%, up 2.9% for the year.  
- Notable stock movements included CANG rising 29.73% despite a year-to-date decline of 68%, and MTC dropping 6.73% with an annual gain of 78.4%.

Top Gainers&Losers

Cango

ECARX

Accendra Health

Zai Lab

Bit Digital

MMTEC

Hesai

GigaCloud Tech

ATRenew

Top 5 CDRs Gainers/Losers (>100M) (4.20)

ZEPP

Intchains(ICG) rose 25.84%, with a trading turnover 27.2 Million USD, and a year-to-date fell 6.1%. Zepp Health(ZEPP) rose 16.39%, with a trading turnover 1.3 Million USD, and a year-to-date fell 39.4%. Cango(CANG) fell 23.55%, with a trading turnover 1.4 Million USD, and a year-to-date fell 75.3%. Lufax(LU) fell 6.9%, with a trading turnover 21.4 Million USD, and a year-to-date fell 26.2%.

- The Nasdaq Composite Index rose by 1.52%, with a year-to-date increase of 5.3%.  
- The S&P 500 increased by 1.2%, while the Dow Jones gained 1.79%, resulting in year-to-date rises of 4.1% and 2.9%, respectively.  
- Notable stock movements include a 25.84% rise for ICG and a 23.55% decline for CANG, reflecting varying year-to-date performances.

Connect Biopharma(CNTB.US)